Beasley, Allen, Crow, Methvin, Portis & Miles, P.C.

The herbal weight loss supplement Que She, advertised as “Slimming Factor Capsule” and as “an all-natural blend of Chinese herbs,” widely distributed on Internet sites such as the Bouncing Bear Botanicals website and at retail outlets such as Sacred Journey in Lawrence, Kansas, has been found to contain ingredients that can cause serious harm to consumers, according to an analysis conducted by the Food and Drug Administration (FDA).

Read the rest of this entry »

The Food and Drug Administration (FDA) is reviewing data from two clinical trials that suggest the blood pressure medication Benicar (olmesartan) may increase the risk of death from cardiovascular causes in patients with type 2 diabetes, according to an FDA safety announcement. The agency is continuing to review the data from two studies, ROADMAP and ORIENT, and is considering additional ways to asses the cardiovascular effects of Benicar.

Read the rest of this entry »

A medication primarily used to treat men with prostate cancer has been associated with a slightly increased risk for diabetes, heart attack, stroke and sudden death. The findings are preliminary and are part of an ongoing analysis of several studies by the Food and Drug Administration (FDA).

Read the rest of this entry »

Off-label marketing is an illegal yet commonly employed sales strategy that some big pharmaceutical companies practice to broaden the appeal of a drug and boost sales. One of the most blatant examples of off-label marketing involved Bayer Healthcare’s blockbuster birth control pill Yaz. Bayer promoted the drug as a treatment for premenstrual dysphoric disorder (PMDD) symptoms and to clear up moderate cases of acne when the FDA approved it as birth control only. Bayer stopped the deceptive marketing of Yaz when the FDA cited it for false and misleading advertising.

Read the rest of this entry »